2026-04-28T08:52:33Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/48752022-10-03T09:46:44Zcom_10259_3924com_10259_5086com_10259_2604col_10259_3925

Manuel Manresa, Pilar . 0e8b3cef-7ea1-44a8-af01-7b49c8f0e385 500 Korrodi Gregório, Luís 43527108-bb37-4519-b366-a78c4f287b53 500 Hernando Santa Cruz, Elsa 279 500 Villanueva, Alberto . ea01f99f-5701-4b73-85dc-d2bd3e31eb70 500 Martínez García, David 18e02fd6-ef02-4fc0-a41e-ce87d3ba38c1 600 Rodilla, Ananda M. 5c2d53ae-ffde-4780-be5a-e5d395b46b91 500 Ramos, Ricard . 2d496323-3f9e-465c-8fdc-f0abf4e8231e 500 Fardilha, Margarida . 8feae4d1-bfa0-4fef-9cf6-e4e345525fcc 500 Moya, Juan . cad76414-77bf-4389-a9b8-f77891d2e598 500 Quesada Pato, Roberto 458 500 Soto Cerrato, Vanessa 346bb3c7-0c69-4d62-9045-26b0b8d37a51 500 Pérez Tomás, Ricardo 3306d7a2-706a-47ab-8490-869a1b191c58 500 2018-08-22T08:28:41Z 2018-08-22T08:28:41Z 2017-07 1535-7163 http://hdl.handle.net/10259/4875 10.1158/1535-7163.MCT-16-0752 Lung cancer has become the leading killer cancer worldwide, due to late diagnosis and lack of efficient anticancer drugs. We have recently described novel natural-derived tambjamine analogues that are potent anion transporters capable of disrupting cellular ion balance, inducing acidification of the cytosol and hyperpolarization of cellular plasma membranes. Although these tambjamine analogues were able to compromise cell survival, their molecular mechanism of action remains largely unknown. Herein we characterize the molecular cell responses induced by highly active indole-based tambjamine analogues treatment in lung cancer cells. Expression changes produced after compounds treatment comprised genes related to apoptosis, cell cycle, growth factors and its receptors, protein kinases and topoisomerases, among others. Dysregulation of BCL2 and BIRC5/survivin genes suggested the apoptotic pathway as the induced molecular cell death mechanism. In fact, activation of several proapoptotic markers (caspase-9, caspase-3, and PARP) and reversion of the cytotoxic effect upon treatment with an apoptosis inhibitor (Z-VAD-FMK) were observed. Moreover, members of the Bcl-2 protein family suffered changes after tambjamine analogues treatment, with a concomitant protein decrease towards the prosurvival members. Besides this, it was observed cellular accumulation of ROS upon compound treatment and an activation of the stress-kinase p38 MAPK route that, when inhibited, reverted the cytotoxic effect of the tambjamine analogues. Finally, a significant therapeutic effect of these compounds was observed in subcutaneous and orthotopic lung cancer mice models. Taken together, these results shed light on the mechanism of action of novel cytotoxic anionophores and demonstrate the therapeutic effects against lung cancer. Spanish Government and EU funds through the Fondo de Investigaciones Sanitarias (FIS, project PI13/ 00089) and from La Marat o de TV3 Foundation (project 20132730) to R. P erez-Tom as. R. Ramos was supported by the Sociedad Espa~nola de Neumología y Cirugía Tor acica (SEPAR, Project 017/2013), R. Quesada by the Consejería de Educación de la Junta de Castilla y León (project BU340U13) and by the La Marat o de TV3 Foundation (project 20132732) and A. Villanueva by the FIS (project PI13/01339). application/pdf eng American Association for Cancer Research Molecular Cancer Therapeutics, 2017, V. 16, n. 7, p. 1224-1235 https://doi.org/10.1158/1535-7163.MCT-16-0752 info:eu-repo/grantAgreement/MSCBS/PI13-00089 info:eu-repo/grantAgreement/TV3Foundation/20132730 info:eu-repo/grantAgreement/SEPAR/017-2013 info:eu-repo/grantAgreement/JCyL/BU340U13 info:eu-repo/grantAgreement/TV3Foundation/20132732 info:eu-repo/grantAgreement/MSCBS/PI13-01339 Química orgánica Chemistry, Organic Novel indole-based tambjamine-analogues induce apoptotic lung cancer cell death through p38 mitogen-activated protein kinase activation info:eu-repo/semantics/article info:eu-repo/semantics/acceptedVersion info:eu-repo/semantics/openAccess THUMBNAIL Manuel-MCT_2017.pdf.jpg Manuel-MCT_2017.pdf.jpg IM Thumbnail image/jpeg 4287 https://riubu.ubu.es/bitstream/10259/4875/4/Manuel-MCT_2017.pdf.jpg 823791b066338d43e6dc7ae1d51efafc MD5 4 ORIGINAL Manuel-MCT_2017.pdf Manuel-MCT_2017.pdf application/pdf 7842678 https://riubu.ubu.es/bitstream/10259/4875/1/Manuel-MCT_2017.pdf 675dc3e7faa7d862918d02078249f34f MD5 1 LICENSE license.txt license.txt text/plain; charset=utf-8 999 https://riubu.ubu.es/bitstream/10259/4875/2/license.txt b295bcbce42e2caabeb0c623d3860c06 MD5 2 TEXT Manuel-MCT_2017.pdf.txt Manuel-MCT_2017.pdf.txt Extracted text text/plain 57518 https://riubu.ubu.es/bitstream/10259/4875/3/Manuel-MCT_2017.pdf.txt f574202e20b9183ea764690740721871 MD5 3 10259/4875 oai:riubu.ubu.es:10259/4875 2022-10-03 11:46:44.819 Repositorio Institucional de la Universidad de Burgos bubrep@ubu.es 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